R
Reuven J. Schore
Researcher at George Washington University
Publications - 40
Citations - 695
Reuven J. Schore is an academic researcher from George Washington University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 32 publications receiving 456 citations. Previous affiliations of Reuven J. Schore include Children's National Medical Center & Columbia University.
Papers
More filters
Journal ArticleDOI
The genomic landscape of juvenile myelomonocytic leukemia.
Elliot Stieglitz,Amaro Taylor-Weiner,Tiffany Y. Chang,Laura C. Gelston,Yong Dong Wang,Tali Mazor,Emilio Esquivel,Ariel Yu,Sara Seepo,Scott R. Olsen,Mara Rosenberg,Sophie Archambeault,Ghada Abusin,Kyle Beckman,Patrick A. Brown,Michael Briones,Benjamin Carcamo,Todd Cooper,Gary V. Dahl,Peter D. Emanuel,Mark Fluchel,Rakesh K. Goyal,Robert J. Hayashi,Johann Hitzler,Christopher Hugge,Y. Lucy Liu,Yoav Messinger,Donald H. Mahoney,Philip M. Monteleone,Eneida R. Nemecek,Philip A. Roehrs,Reuven J. Schore,Kimo C. Stine,Clifford M. Takemoto,Jeffrey A. Toretsky,Joseph F. Costello,Adam B. Olshen,Chip Stewart,Yongjin Li,Jing Ma,Robert B. Gerbing,Todd A. Alonzo,Gad Getz,Gad Getz,Tanja A. Gruber,Todd R. Golub,Todd R. Golub,Kimberly Stegmaier,Kimberly Stegmaier,Mignon L. Loh +49 more
TL;DR: Genomically characterize serial samples from patients at diagnosis through relapse and transformation to acute myeloid leukemia to expand knowledge of the mutational spectrum in JMML and identified recurrent mutations in genes involved in signal transduction, splicing, Polycomb repressive complex 2 (PRC2) and transcription.
Journal ArticleDOI
Impact of Asparaginase Discontinuation on Outcome in Childhood Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group
Sumit Gupta,Cindy Wang,Elizabeth A. Raetz,Reuven J. Schore,Wanda L. Salzer,Eric Larsen,Kelly W. Maloney,Len A. Mattano,William L. Carroll,Naomi J. Winick,Stephen P. Hunger,Mignon L. Loh,Meenakshi Devidas +12 more
TL;DR: Discontinuation of ASNase doses is associated with inferior DFS in higher-risk patients and illustrates the severe consequences of Erwinia shortages.
Journal ArticleDOI
Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4
Anne L. Angiolillo,Reuven J. Schore,Meenakshi Devidas,Michael J. Borowitz,Andrew J. Carroll,Julie M. Gastier-Foster,Nyla A. Heerema,Taha Keilani,Ashley R. Lane,Mignon L. Loh,Gregory H. Reaman,Peter C. Adamson,Brent L. Wood,Charlotte Wood,Hao W. Zheng,Elizabeth A. Raetz,Naomi J. Winick,William L. Carroll,Stephen P. Hunger +18 more
TL;DR: SC-PEG2500 achieves a significantly longer period of asparaginase activity above defined thresholds and asparagine depletion compared with SS-Peg2500 and has a comparable toxicity profile in children with HR B-cell ALL.
Journal ArticleDOI
Echinomycin protects mice against relapsed acute myeloid leukemia without adverse effect on hematopoietic stem cells.
Yin Wang,Yan Liu,Fei Tang,Kelsie M. Bernot,Reuven J. Schore,Guido Marcucci,Michael A. Caligiuri,Pan Zheng,Yang Liu +8 more
TL;DR: It is demonstrated that in a mouse model of relapsed AML, low-dose echinomycin selectively targets LICs and spares normal hematopoiesis and in mice with complete remission, echinomecin appeared to completely eliminate LICs.
Journal ArticleDOI
Severe pegaspargase hypersensitivity reaction rates (grade ≥3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials.
Michael J. Burke,Meenakshi Devidas,Kelly W. Maloney,Anne L. Angiolillo,Reuven J. Schore,Kimberly P. Dunsmore,Eric Larsen,Len A. Mattano,Wanda L. Salzer,Stuart S. Winter,William L. Carroll,Naomi J. Winick,Mignon L. Loh,Elizabeth A. Raetz,Stephen P. Hunger,Archie Bleyer +15 more
TL;DR: On standardized treatment protocols conducted by the COG during 2003–2015, grade ≥3 HSR rates to pegaspargase occurred less frequently with IV infusion than IM injection.